Antibody Information
General Information of This Antibody (ID: ANTI0MDGYS)
| Antibody Name | Anti-Onco-foetal sialyl-Tn antibody |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | Onco-foetal sialyl-Tn |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SGN-STNV [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants had advanced solid tumors (NSCLC, breast, GI, and gynecologic cancers) refractory to standard therapies, measurable disease per RECIST v1.1, and adequate organ function. Key exclusions included active CNS metastases, prior MMAE therapy, ≥Grade 2 neuropathy, or uncontrolled ≥Grade 3 infections. Biopsies were required for specific cohorts.
Click to Show/Hide
|
||||
| Administration Dosage |
Part A (dose escalation) and Part B (dose expansion) will include up to 25 and 180 patients (in up to 6 expansion cohorts), respectively.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04665921 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
|
||||
| Primary Endpoint |
Safety endpoints included incidence of AEs, lab abnormalities, and dose-limiting toxicities monitored up to 30-37 days post-treatment or approximately 3 years, analyzed descriptively.
|
||||
| Other Endpoint |
Efficacy measures (ORR, PFS, OS, DOR) and PK/immunogenicity parameters (AUC, Tmax, Cmax, Ctrough, ADA) were evaluated over approximately 3 years to assess treatment response and drug exposure characteristics.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04665921 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 study of SGN-STNV in advanced solid tumors.
|
||||
References